Overview
Argenx SE is a global biotechnology company based in the Netherlands. The company operates within the primary industry of healthcare, specifically focusing on the development and commercialization of antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Argenx's key project is its lead product candidate, efgartigimod, which is being developed for multiple severe autoimmune indications.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for argenx SE as of 30 June 2025 is 3,120.82 MM.
- The operating income for argenx SE as of 30 June 2025 is 462.81 MM.
- The net income for argenx SE as of 30 June 2025 is 1,280.40 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 3,120.82 | 462.81 | 1,280.40 |
2025-03-31 | 2,643.06 | 215.03 | 1,064.11 |
2024-12-31 | 2,248.20 | -17.84 | 833.04 |
2024-09-30 | 1,908.66 | -256.24 | -40.29 |
2024-06-30 | 1,659.62 | -352.25 | -204.34 |
2024-03-31 | 1,451.23 | -408.79 | -327.78 |
2023-12-31 | 1,268.59 | -420.64 | -295.05 |
2023-09-30 | 1,028.61 | -401.81 | -234.50 |
2023-06-30 | 835.26 | -530.61 | -396.90 |
2023-03-31 | 639.41 | -604.67 | -511.28 |
2022-12-31 | 441.01 | -723.92 | -709.59 |
2022-09-30 | 285.68 | -847.97 | -908.80 |
2022-06-30 | 146.30 | -852.29 | -907.37 |
2022-03-31 | 381.18 | -582.61 | -595.02 |
2021-12-31 | 528.27 | -359.90 | -408.26 |
2021-09-30 | 510.08 | -274.22 | -372.60 |
2021-06-30 | 526.29 | -162.57 | -318.70 |
2021-03-31 | 205.61 | -398.03 | -572.97 |
2020-12-31 | 61.96 | -480.57 | -608.46 |
2020-09-30 | 63.99 | -380.37 | -456.20 |
2020-06-30 | |||
2020-03-31 |
Income Statement: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | -0.68 | -0.67 |
2024-06-30 | -3.46 | -3.47 |
2024-03-31 | -5.64 | -5.64 |
2023-12-31 | -5.16 | |
2023-09-30 | -4.17 | -4.17 |
2023-06-30 | -7.15 | -7.15 |
2023-03-31 | -9.25 | -9.25 |
2022-12-31 | -13.05 | |
2022-09-30 | -17.01 | -17.01 |
2022-06-30 | -17.29 | -17.29 |
2022-03-31 | -11.53 | -11.53 |
2021-12-31 | -7.99 | |
2021-09-30 | -7.24 | -7.24 |
2021-06-30 | -6.51 | -6.51 |
2021-03-31 | -12.14 | -12.14 |
2020-12-31 | -13.40 | |
2020-09-30 | -10.43 | -10.43 |
2020-06-30 | -8.66 | -8.66 |
2020-03-31 | -6.25 | -6.25 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for argenx SE as of 30 June 2025 is 403.75 MM.
- The cash from investing activities for argenx SE as of 30 June 2025 is -141.53 MM.
- The cash from financing activities for argenx SE as of 30 June 2025 is 313.18 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | 403.75 | -141.53 | 313.18 |
2025-03-31 | |||
2024-12-31 | -82.75 | -717.59 | 279.76 |
2024-09-30 | |||
2024-06-30 | -259.55 | -732.57 | 1,314.51 |
2024-03-31 | |||
2023-12-31 | -420.33 | 308.21 | 1,336.73 |
2023-09-30 | |||
2023-06-30 | -653.73 | 298.18 | 97.77 |
2023-03-31 | |||
2022-12-31 | -862.81 | -461.18 | 843.76 |
2022-09-30 | |||
2022-06-30 | -876.26 | -87.09 | 826.29 |
2022-03-31 | |||
2021-12-31 | -606.81 | -347.07 | 1,121.34 |
2021-09-30 | |||
2021-06-30 | -473.67 | -450.61 | 1,119.75 |
2021-03-31 | |||
2020-12-31 | -398.46 | 344.69 | 833.00 |
2020-09-30 | |||
2020-06-30 | |||
2020-03-31 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 | |||
2020-03-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 | ||
2020-06-30 | ||
2020-03-31 |
Management Effectiveness
- The roa for argenx SE as of 30 June 2025 is 0.22.
- The roe for argenx SE as of 30 June 2025 is 0.25.
- The roic for argenx SE as of 30 June 2025 is 0.19.
- The croic for argenx SE as of 30 June 2025 is -0.10.
- The ocroic for argenx SE as of 30 June 2025 is -0.01.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2025-06-30 | 0.22 | 0.25 | 0.19 | -0.10 | -0.01 |
2025-03-31 | 0.18 | 0.26 | 0.15 | -0.10 | -0.01 |
2024-12-31 | -0.01 | 0.20 | -0.01 | 0.08 | -0.06 |
2024-09-30 | -0.06 | -0.01 | -0.05 | 0.08 | -0.06 |
2024-06-30 | -0.10 | -0.12 | -0.08 | 0.30 | -0.10 |
2024-03-31 | -0.09 | -0.10 | -0.07 | 0.30 | -0.10 |
2023-12-31 | -0.07 | -0.08 | -0.08 | -0.09 | -0.23 |
2023-09-30 | -0.12 | -0.13 | -0.14 | -0.09 | -0.23 |
2023-06-30 | -0.16 | -0.13 | -0.14 | -0.09 | -0.23 |
2023-03-31 | -0.25 | -0.20 | -0.18 | -0.19 | -0.31 |
2022-12-31 | -0.28 | -0.31 | -0.30 | 0.00 | 0.00 |
2022-09-30 | -0.28 | -0.31 | -0.30 | -0.07 | -0.29 |
2022-06-30 | -0.19 | -0.31 | -0.30 | -0.07 | -0.29 |
2022-03-31 | -0.18 | -0.36 | -0.23 | 0.05 | -0.24 |
2021-12-31 | -0.20 | -0.24 | -0.16 | 0.05 | 0.00 |
2021-09-30 | -0.18 | -0.23 | -0.13 | 0.06 | -0.16 |
2021-06-30 | -0.15 | -0.21 | -0.11 | 0.06 | -0.16 |
2021-03-31 | -0.34 | -0.53 | -0.33 | 0.50 | -0.24 |
2020-12-31 | -0.42 | -0.52 | -0.44 | 0.62 | -0.25 |
2020-09-30 | -0.45 | -0.69 | -0.28 | 0.64 | -0.16 |
2020-06-30 | -0.32 | -0.49 | -0.18 | 0.63 | -0.14 |
2020-03-31 | -0.43 | -0.46 | -0.24 | 0.05 | 0.14 |
Gross Margins
- The gross margin for argenx SE as of 30 June 2025 is 0.50.
- The net margin for argenx SE as of 30 June 2025 is 0.40.
- The operating margin for argenx SE as of 30 June 2025 is 0.08.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2025-06-30 | 0.50 | 0.40 | 0.08 |
2025-03-31 | 0.46 | 0.37 | -0.01 |
2024-12-31 | 0.38 | -0.02 | -0.13 |
2024-09-30 | 0.33 | -0.12 | -0.21 |
2024-06-30 | 0.27 | -0.23 | -0.28 |
2024-03-31 | 0.23 | -0.23 | -0.33 |
2023-12-31 | 0.23 | -0.23 | -0.39 |
2023-09-30 | 0.03 | -0.48 | -0.64 |
2023-06-30 | -0.13 | -0.48 | -0.64 |
2023-03-31 | -0.57 | -0.80 | -0.95 |
2022-12-31 | -1.45 | -3.06 | -2.82 |
2022-09-30 | -3.05 | -3.06 | -2.82 |
2022-06-30 | -0.60 | -6.20 | -5.83 |
2022-03-31 | -0.08 | -1.52 | -1.46 |
2021-12-31 | -0.01 | -0.76 | -0.65 |
2021-09-30 | 0.09 | -0.73 | -0.50 |
2021-06-30 | 0.09 | -0.65 | -0.37 |
2021-03-31 | -0.94 | -2.75 | -1.87 |
2020-12-31 | -4.97 | -9.37 | -7.36 |
2020-09-30 | -4.02 | -7.13 | -5.94 |
2020-06-30 | -4.19 | -5.18 | -5.25 |
2020-03-31 | -2.91 | -3.79 | -4.09 |
Identifiers and Descriptors
Central Index Key (CIK) | 1697862 |